Irreversible myeloperoxidase inhibitor mitiperstat and mitiperstat metabolites display immunogenicity in humans

Clicks: 4
ID: 337402
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #150 of 151 articles by views in toxicological sciences : an official journal of the society of toxicology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 151 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Myeloperoxidase (MPO) dysregulation contributes to cardiovascular disease, making MPO a promising therapeutic target. Mitiperstat, an irreversible 2-thioxanthine MPO inhibitor in clinical development, has been linked to delayed-onset maculopapular rash. This study investigated whether mitiperstat and its metabolites (M7, M9, M10, M12) activate human T-cells in vitro. De novo T-cell responses from healthy donors were assessed using a dendritic cell:T-cell co-culture assay, and T-cell clones (TCCs) were characterised for compound specificity, phenotype, function and cross-reactivity. Proliferation was measured by [3H]-thymidine incorporation, and cytokine/cytolytic molecule release (IFN-γ, IL-5, IL-13, granzyme-B) by ELISpot. Twenty-nine predominantly CD4+ TCCs were specific to mitiperstat, while forty-seven CD4+ and CD8+ TCCs responded to its metabolites. All drug-specific TCCs proliferated dose-dependently and secreted a heterogeneous Th1/Th2 cytokine and cytolytic profile. CD4+ and CD8+ TCC activation was attenuated by MHC-class II and MHC-class I blockade, respectively. Despite the irreversible on-target pharmacology of mitiperstat, nearly all responsive TCCs were activated via direct pharmacological interactions with proliferation occurring with drug or respective metabolite in the presence of glutaraldehyde-fixed antigen-presenting cells. In contrast, one TCC was activated with drug-pulsed antigen presenting cells. TCCs showed high specificity for their cognate compounds with no cross-reactivity. These findings demonstrate the intrinsic immunogenicity of mitiperstat and its metabolites and establish a framework for assessing and comparing T-cell reactivity of future MPO-targeting therapies.
Reference Key
openalex_W7223948486 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Lonnie I J MacDonald, Silvia Martinez-Rivera, Georgia Wells, Joshua Gardner, Paul Thomson, Carl A. Whatling, Erik Michaëlsson, Liam Farrell, Xiaoli Meng, Catherine Jean Betts, Dean John Naisbitt
Journal toxicological sciences : an official journal of the society of toxicology
Year 2026
DOI
10.1093/toxsci/kfag140
URL
https://doi.org/10.1093/toxsci/kfag140
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.